JP2010535495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535495A5 JP2010535495A5 JP2010519544A JP2010519544A JP2010535495A5 JP 2010535495 A5 JP2010535495 A5 JP 2010535495A5 JP 2010519544 A JP2010519544 A JP 2010519544A JP 2010519544 A JP2010519544 A JP 2010519544A JP 2010535495 A5 JP2010535495 A5 JP 2010535495A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- vsv
- compounds according
- lentiviral vector
- envelope protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 62
- 239000013598 vector Substances 0.000 claims 40
- 101710091045 Envelope protein Proteins 0.000 claims 23
- 102100034349 Integrase Human genes 0.000 claims 23
- 101710188315 Protein X Proteins 0.000 claims 23
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 19
- 241000725303 Human immunodeficiency virus Species 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 241000700605 Viruses Species 0.000 claims 14
- 239000002245 particle Substances 0.000 claims 14
- 241001430294 unidentified retrovirus Species 0.000 claims 12
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 11
- 101710177291 Gag polyprotein Proteins 0.000 claims 10
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 10
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 239000002157 polynucleotide Substances 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 208000015181 infectious disease Diseases 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 102100034347 Integrase Human genes 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000013612 plasmid Substances 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 230000028993 immune response Effects 0.000 claims 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 5
- 206010061598 Immunodeficiency Diseases 0.000 claims 5
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 5
- 230000007813 immunodeficiency Effects 0.000 claims 5
- 230000037452 priming Effects 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 4
- 230000000798 anti-retroviral effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 101710170658 Endogenous retrovirus group K member 10 Gag polyprotein Proteins 0.000 claims 3
- 101710186314 Endogenous retrovirus group K member 21 Gag polyprotein Proteins 0.000 claims 3
- 101710162093 Endogenous retrovirus group K member 24 Gag polyprotein Proteins 0.000 claims 3
- 101710094596 Endogenous retrovirus group K member 8 Gag polyprotein Proteins 0.000 claims 3
- 101710177443 Endogenous retrovirus group K member 9 Gag polyprotein Proteins 0.000 claims 3
- 108091006027 G proteins Proteins 0.000 claims 3
- 102000030782 GTP binding Human genes 0.000 claims 3
- 108091000058 GTP-Binding Proteins 0.000 claims 3
- 101710203526 Integrase Proteins 0.000 claims 3
- 230000005867 T cell response Effects 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 230000001177 retroviral effect Effects 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 108010061833 Integrases Proteins 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 241000712464 Orthomyxoviridae Species 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 241000710924 Togaviridae Species 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 241000712892 Arenaviridae Species 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000710781 Flaviviridae Species 0.000 claims 1
- 108060003393 Granulin Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims 1
- 241000711504 Paramyxoviridae Species 0.000 claims 1
- 108010076039 Polyproteins Proteins 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000712907 Retroviridae Species 0.000 claims 1
- 241000711931 Rhabdoviridae Species 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 206010058874 Viraemia Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940124522 antiretrovirals Drugs 0.000 claims 1
- 239000003903 antiretrovirus agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000007969 cellular immunity Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000005220 cytoplasmic tail Anatomy 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 108010089520 pol Gene Products Proteins 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290980.7A EP2020444B1 (en) | 2007-08-03 | 2007-08-03 | Defective non-integrative lentiviral transfer vectors for vaccines |
| EP07290979.9 | 2007-08-03 | ||
| EP07290980.7 | 2007-08-03 | ||
| EP07290979 | 2007-08-03 | ||
| EP07291251.2A EP2047861B1 (en) | 2007-10-12 | 2007-10-12 | Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications |
| EP07291251.2 | 2007-10-12 | ||
| EP08156405 | 2008-05-16 | ||
| EP08156405.6 | 2008-05-16 | ||
| PCT/IB2008/002930 WO2009019612A2 (en) | 2007-08-03 | 2008-08-01 | Lentiviral gene transfer vectors and their medicinal applications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237117A Division JP2015062425A (ja) | 2007-08-03 | 2014-11-21 | レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535495A JP2010535495A (ja) | 2010-11-25 |
| JP2010535495A5 true JP2010535495A5 (OSRAM) | 2011-09-15 |
| JP5773648B2 JP5773648B2 (ja) | 2015-09-02 |
Family
ID=40341833
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519544A Active JP5773648B2 (ja) | 2007-08-03 | 2008-08-01 | レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用 |
| JP2014237117A Pending JP2015062425A (ja) | 2007-08-03 | 2014-11-21 | レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用 |
| JP2018000479A Active JP6480028B2 (ja) | 2007-08-03 | 2018-01-05 | レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237117A Pending JP2015062425A (ja) | 2007-08-03 | 2014-11-21 | レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用 |
| JP2018000479A Active JP6480028B2 (ja) | 2007-08-03 | 2018-01-05 | レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8420104B2 (OSRAM) |
| EP (1) | EP2185192B1 (OSRAM) |
| JP (3) | JP5773648B2 (OSRAM) |
| CN (2) | CN102083462B (OSRAM) |
| AU (1) | AU2008285224B2 (OSRAM) |
| BR (1) | BRPI0813194B8 (OSRAM) |
| CA (1) | CA2695433C (OSRAM) |
| DK (1) | DK2185192T3 (OSRAM) |
| ES (1) | ES2708856T3 (OSRAM) |
| HK (1) | HK1252608A1 (OSRAM) |
| IL (1) | IL243569A (OSRAM) |
| MX (2) | MX2010001379A (OSRAM) |
| PT (1) | PT2185192T (OSRAM) |
| WO (1) | WO2009019612A2 (OSRAM) |
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0701253D0 (en) | 2007-01-23 | 2007-02-28 | Diagnostics For The Real World | Nucleic acid amplification and testing |
| AU2008285224B2 (en) | 2007-08-03 | 2015-01-22 | Centre National De La Recherche Scientifique (Cnrs) | Lentiviral gene transfer vectors and their medicinal applications |
| WO2010129602A2 (en) | 2009-05-04 | 2010-11-11 | Fred Hutchinson Cancer Research Center | Cocal vesiculovirus envelope pseudotyped retroviral vectors |
| EP2366776A1 (en) * | 2010-03-01 | 2011-09-21 | Epixis | A method for measuring viral infectivity |
| DK2385107T3 (en) | 2010-05-03 | 2016-12-12 | Pasteur Institut | Lentiviral vector-based immunological compounds against malaria |
| EP2666477A1 (en) | 2012-05-23 | 2013-11-27 | Theravectys | Lentiviral vectors containing an MHC class I promoter |
| WO2011147622A1 (en) | 2010-05-26 | 2011-12-01 | Deutsches Rheuma-Forschungszentrum Berlin | Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells |
| CN102277380B (zh) * | 2010-06-08 | 2013-03-27 | 齐鲁制药有限公司 | 一种dhfr互补表达的共转染真核表达载体及其制备方法与应用 |
| KR20130036354A (ko) | 2010-06-25 | 2013-04-11 | 오말코 네트워크 솔루션스 리미티드 | 연성 기판에 대한 보안 개선 |
| EP2643343A1 (en) | 2010-11-26 | 2013-10-02 | Institut Pasteur | Identification of a human gyrovirus and applications. |
| WO2012141984A1 (en) | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| WO2013083753A2 (en) | 2011-12-07 | 2013-06-13 | Institut Pasteur | Identification of a swine parecho-like virus and applications |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| WO2013140169A1 (en) * | 2012-03-20 | 2013-09-26 | Isis Innovation Limited | Immunogenic composition and methods of use thereof |
| NZ700340A (en) | 2012-03-30 | 2017-02-24 | Immune Design Corp | Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| WO2014016383A2 (en) | 2012-07-25 | 2014-01-30 | Theravectys | Glycoproteins for pseudotyping lentivectors |
| FR2996856B1 (fr) * | 2012-10-15 | 2015-06-05 | Agronomique Inst Nat Rech | Novirhabdovirus recombinant utilisable comme vecteur d'antigenes |
| CA2932542C (en) * | 2012-12-14 | 2023-06-06 | The Regents Of The University Of California | Viral vector nanocapsule for targeting gene therapy and its preparation |
| KR20160011645A (ko) * | 2013-06-03 | 2016-02-01 | 떼라벡띠스 | MHC 클래스 I, MHC 클래스 II 또는 β2 마이크로글로불린 업스트림 프로모터 서열을 포함하는 렌티바이러스 벡터들 |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| WO2015063706A1 (en) * | 2013-10-31 | 2015-05-07 | Theravectys | Lentiviral vectors for expression of hiv-1 antigens |
| EP3009144A1 (en) * | 2014-10-15 | 2016-04-20 | Theravectys | Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans |
| EP2878674A1 (en) * | 2013-11-28 | 2015-06-03 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Stable episomes based on non-integrative lentiviral vectors |
| EP2878667A1 (en) | 2013-11-29 | 2015-06-03 | Institut Pasteur | TAL effector means useful for partial or full deletion of DNA tandem repeats |
| US9987351B2 (en) | 2014-01-27 | 2018-06-05 | Theravectys | Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1 |
| MX369776B (es) * | 2014-03-01 | 2019-11-21 | Univ Texas | Vectores recombinantes del virus isfahan. |
| IL292574A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| EP3031923A1 (en) | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| EP3211003A1 (en) | 2016-02-24 | 2017-08-30 | Institut Pasteur | T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| EP3235828A1 (en) * | 2016-04-21 | 2017-10-25 | Genethon | Stable pseudotyped lentiviral particles and uses thereof |
| WO2017194902A2 (fr) * | 2016-05-13 | 2017-11-16 | Vectalys | Particule pour l'encapsidation d'un système d'ingénierie du génome |
| CN106399376A (zh) * | 2016-08-31 | 2017-02-15 | 河南省华隆生物技术有限公司 | 一种整合缺陷型慢病毒载体、其制备方法及应用 |
| BR112019013862A2 (pt) | 2017-01-07 | 2020-04-14 | Selecta Biosciences Inc | dosagem padrão de imunossupressores acoplados a nanocarreadores sintéticos |
| WO2018140946A1 (en) | 2017-01-30 | 2018-08-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant virus vectors for the treatment of glycogen storage disease |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| AU2018241252B2 (en) | 2017-03-30 | 2024-09-19 | The University Of Queensland | Chimeric molecules and uses thereof |
| FR3065967B1 (fr) * | 2017-05-05 | 2022-06-03 | Univ Paris Descartes | Procede in vitro de detection et de quantification de l'adn du vih-2 |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| WO2019040994A1 (en) | 2017-09-01 | 2019-03-07 | The Australian National University | IMMUNOREGULATOR MOLECULES AND USES THEREOF |
| JP2020534007A (ja) | 2017-09-22 | 2020-11-26 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック | 変異型ウイルスタンパク質 |
| US12295978B2 (en) * | 2017-09-28 | 2025-05-13 | Shiftbio Inc. | Recombinant plasma membrane-based vesicle, for treating cancer |
| JP6994714B2 (ja) | 2017-10-03 | 2022-01-14 | 東亞合成株式会社 | 抗ウイルス性ペプチドおよびその利用 |
| KR20200086670A (ko) | 2017-10-13 | 2020-07-17 | 셀렉타 바이오사이언시즈, 인크. | 항바이러스 전달 벡터 IgM 반응을 약화시키기 위한 방법 및 조성물 |
| WO2019077150A1 (en) * | 2017-10-20 | 2019-04-25 | Genethon | USE OF SYNCYTIN TO TARGET A MEDICINAL PRODUCT AND GENE ADMINISTRATION TO PULMONARY TISSUE |
| CN111683959A (zh) | 2017-11-09 | 2020-09-18 | 巴斯德研究院 | 包含非结构蛋白的寨卡病毒嵌合多表位及其在免疫原性组合物中的用途 |
| KR20200139679A (ko) | 2018-02-26 | 2020-12-14 | 안톨알엑스, 인크. | 면역관용성 리포솜 및 그의 사용 방법 |
| JP6917942B2 (ja) | 2018-04-11 | 2021-08-11 | 株式会社日立製作所 | データ分析サーバ、データ分析システム、及びデータ分析方法 |
| CN110577585A (zh) * | 2018-06-07 | 2019-12-17 | 中国医学科学院基础医学研究所 | 水泡型口炎病毒包膜糖蛋白变体及其构建方法和应用 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| WO2020115114A1 (en) * | 2018-12-04 | 2020-06-11 | Sirion Biotech Gmbh | Viral transduction using poloxamines |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CA3132840A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| EP3708176A1 (en) * | 2019-03-15 | 2020-09-16 | Centre National De La Recherche Scientifique -Cnrs- | Mutant vsv ectodomain polypeptide and uses thereof |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| KR20220004121A (ko) | 2019-04-28 | 2022-01-11 | 셀렉타 바이오사이언시즈, 인크. | 바이러스 전달 벡터에 대한 기존의 면역을 갖는 대상체의 치료 방법 |
| US20240124889A1 (en) | 2019-05-07 | 2024-04-18 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN114206396A (zh) | 2019-05-28 | 2022-03-18 | 西莱克塔生物科技公司 | 用于减弱抗病毒转移载体免疫应答的方法和组合物 |
| CA3143327A1 (en) | 2019-06-13 | 2020-12-17 | J. Keith Joung | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| EP3770264A1 (en) | 2019-07-22 | 2021-01-27 | Genethon | Precise integration using nuclease targeted idlv |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| US20210332448A1 (en) * | 2020-03-09 | 2021-10-28 | Janssen Pharmaceutica Nv | Compositions and methods for quantifying integration of recombinant vector nucleic acid |
| CN111593073B (zh) * | 2020-03-18 | 2022-03-08 | 睿丰康生物医药科技(浙江)有限公司 | 双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒 |
| WO2021188996A1 (en) * | 2020-03-20 | 2021-09-23 | The Broad Institute, Inc. | Compositions and methods for enhanced lentiviral production |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| AU2021337534A1 (en) * | 2020-09-01 | 2023-03-16 | The Trustees Of The University Of Pennsylvania | Improved generation of lentiviral vectors for T cell transduction using cocal envelope |
| KR102379144B1 (ko) * | 2020-09-29 | 2022-03-28 | 한국표준과학연구원 | SARS-CoV-2의 RNA 표준물질 및 이를 이용한 코로나19바이러스(SARS-CoV-2) 감염 진단 정보의 제공방법 |
| KR102283733B1 (ko) * | 2020-12-22 | 2021-08-02 | 한국표준과학연구원 | ＣＯＶＩＤ-19 바이러스 진단을 위한, ＳＡＲＳ-ＣｏＶ-2 포장 ＲＮＡ 표준물질, 이의 제조방법 및 이의 용도 |
| EP4284931A4 (en) * | 2021-01-28 | 2025-06-04 | The Broad Institute, Inc. | Compositions and methods for cargo delivery to a target cell |
| CN114107393A (zh) | 2021-04-07 | 2022-03-01 | 上海劲威生物科技有限公司 | 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用 |
| CN115247190B (zh) * | 2021-04-28 | 2024-06-18 | 沛尔生技医药股份有限公司 | 慢病毒包装系统、其所制得的慢病毒及经该慢病毒转导的细胞及其应用 |
| TWI758171B (zh) | 2021-04-28 | 2022-03-11 | 沛爾生技醫藥股份有限公司 | 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法 |
| CA3217862A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
| EP4362957A1 (en) | 2021-07-01 | 2024-05-08 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| AU2022326565A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| EP4384189A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| KR20240124919A (ko) * | 2021-11-15 | 2024-08-19 | 떼라벡띠스 | 인유두종 바이러스 항원의 발현을 위한 렌티바이러스 벡터 및 이의 hpv 유발 암 치료에 대한 구현 |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
| EP4448776A1 (en) | 2021-12-16 | 2024-10-23 | Ludwig Institute for Cancer Research Ltd | Antisense transfer vectors and methods of use thereof |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| KR20240155390A (ko) | 2022-02-17 | 2024-10-28 | 사나 바이오테크놀로지, 인크. | 조작된 cd47 단백질 및 이의 용도 |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| US20250101382A1 (en) | 2022-03-11 | 2025-03-27 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
| CN120051297A (zh) | 2022-06-30 | 2025-05-27 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024023135A1 (en) * | 2022-07-27 | 2024-02-01 | Theravectys | Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers |
| CN116024269B (zh) * | 2022-11-18 | 2024-02-02 | 复百澳(苏州)生物医药科技有限公司 | 一种冠状病毒假病毒颗粒的制备方法 |
| WO2024129696A1 (en) | 2022-12-12 | 2024-06-20 | Retromer Therapeutics Corp. | Aav and lentiviral constructs comprising a sorl1 mini-gene for use in treating neurodegenerative diseases |
| WO2024151541A1 (en) | 2023-01-09 | 2024-07-18 | Sana Biotechnology, Inc. | Type-1 diabetes autoimmune mouse |
| EP4649162A1 (en) * | 2023-01-10 | 2025-11-19 | Legend Biotech Ireland Limited | Regulatory sequences and uses thereof |
| WO2024178386A1 (en) | 2023-02-24 | 2024-08-29 | Aarhus Universitet | Methods of treating endosomal trafficking diseases |
| WO2024213153A1 (zh) * | 2023-04-13 | 2024-10-17 | 深圳市济因生物科技有限公司 | 一种载体及其应用 |
| WO2024226784A2 (en) * | 2023-04-27 | 2024-10-31 | Genvivo, Inc. | Compositions and methods for therapeutic or vaccine delivery |
| AU2024264889A1 (en) | 2023-05-03 | 2025-11-13 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| WO2024243236A2 (en) | 2023-05-22 | 2024-11-28 | Sana Biotechnology, Inc. | Methods of delivery of islet cells and related methods |
| US12440564B2 (en) | 2023-09-25 | 2025-10-14 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| CN119639818A (zh) * | 2025-02-18 | 2025-03-18 | 南京市计量监督检测院 | 一种假病毒颗粒的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2169073B1 (en) * | 1999-10-11 | 2013-11-13 | Institut Pasteur | Vector for the preparation of immunotherapeutical compositions |
| EP1291419B1 (en) * | 2000-06-01 | 2013-09-18 | Dnavec Research Inc. | Pseudo type retrovirus vector containing membrane protein having hemagglutinin activity |
| WO2002022080A2 (en) | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| US7575924B2 (en) * | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| EP1390516B1 (en) | 2001-05-03 | 2009-03-18 | FIT Biotech Oy | Novel expression vectors and uses thereof |
| JPWO2002101057A1 (ja) | 2001-06-08 | 2004-09-24 | 株式会社ディナベック研究所 | Ｖｓｖ−ｇシュードタイプ化サル免疫不全ウイルスベクターを用いた霊長類胚性幹細胞への遺伝子導入 |
| US7479547B2 (en) | 2001-10-31 | 2009-01-20 | The South African Medical Research Council | HIV-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof |
| US20060257416A1 (en) | 2003-06-13 | 2006-11-16 | Palmowski J M | Materials and methods for improved vaccination |
| US20070275010A1 (en) | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| BRPI0516048A (pt) * | 2004-10-13 | 2008-08-19 | Crucell Holland B V E Beth Isr | batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c |
| WO2006127585A2 (en) * | 2005-05-20 | 2006-11-30 | Virxsys Corporation | Transduction of primary cells |
| AU2006252406B2 (en) * | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| ES2281252B1 (es) | 2005-07-27 | 2009-02-16 | Consejo Superior De Investigaciones Cientificas | Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida. |
| WO2007054792A1 (en) | 2005-11-08 | 2007-05-18 | South African Medical Research Council | Chimaeric hiv-1 subtype c gag-virus-like particles |
| EP1968629A2 (en) | 2005-12-21 | 2008-09-17 | Glaxo Group Limited | Method of eliciting immune response |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| WO2007091066A1 (en) | 2006-02-07 | 2007-08-16 | Ucl Business Plc | Applications of non-integrating lentiviral vectors |
| AU2008285224B2 (en) | 2007-08-03 | 2015-01-22 | Centre National De La Recherche Scientifique (Cnrs) | Lentiviral gene transfer vectors and their medicinal applications |
-
2008
- 2008-08-01 AU AU2008285224A patent/AU2008285224B2/en active Active
- 2008-08-01 CA CA2695433A patent/CA2695433C/en active Active
- 2008-08-01 WO PCT/IB2008/002930 patent/WO2009019612A2/en not_active Ceased
- 2008-08-01 BR BRPI0813194A patent/BRPI0813194B8/pt active IP Right Grant
- 2008-08-01 CN CN200880110278.7A patent/CN102083462B/zh active Active
- 2008-08-01 MX MX2010001379A patent/MX2010001379A/es active IP Right Grant
- 2008-08-01 US US12/671,898 patent/US8420104B2/en active Active
- 2008-08-01 CN CN201511036366.5A patent/CN108114276A/zh active Pending
- 2008-08-01 MX MX2014010835A patent/MX342449B/es unknown
- 2008-08-01 EP EP08827144.0A patent/EP2185192B1/en active Active
- 2008-08-01 PT PT08827144T patent/PT2185192T/pt unknown
- 2008-08-01 DK DK08827144.0T patent/DK2185192T3/en active
- 2008-08-01 ES ES08827144T patent/ES2708856T3/es active Active
- 2008-08-01 JP JP2010519544A patent/JP5773648B2/ja active Active
-
2012
- 2012-04-23 US US13/453,784 patent/US8709799B2/en active Active
-
2014
- 2014-03-05 US US14/197,532 patent/US9328146B2/en active Active
- 2014-11-21 JP JP2014237117A patent/JP2015062425A/ja active Pending
-
2016
- 2016-01-11 IL IL243569A patent/IL243569A/en active IP Right Grant
-
2018
- 2018-01-05 JP JP2018000479A patent/JP6480028B2/ja active Active
- 2018-09-17 HK HK18111908.8A patent/HK1252608A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535495A5 (OSRAM) | ||
| US20120135034A1 (en) | Non-Integrating Retroviral Vector Vaccines | |
| DK2456786T4 (en) | LENTIVIRUS VECTORS DETERMINED PSEUDOTYPE WITH A COAT PEGYCLOPROTEIN FROM SINDBIS VIRUS | |
| CN1688702B (zh) | 表达rna病毒抗原表位的重组麻疹病毒在制备疫苗组合物中的用途 | |
| JP2012520084A5 (OSRAM) | ||
| JP2004537974A5 (OSRAM) | ||
| BR112020011976A2 (pt) | composição e kit imunogênicos contra o vírus da hepatite b, usos dos mesmos, e molécula de ácido nucleico de ocorrência não natural | |
| ES2282041B1 (es) | Mejoras introducidas en el objeto de la patente principal n es200501841 para "vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida". | |
| US20170362607A1 (en) | Use of non-subtype b gag proteins for lentiviral packaging | |
| King et al. | Technical considerations for the generation of novel pseudotyped viruses | |
| WO2012018856A2 (en) | Hiv vaccine therapy with concomitant antiviral monotherapy | |
| JP4989224B2 (ja) | Ｄｎａワクチン組成物およびその使用方法 | |
| AU2004262022B2 (en) | Accelerated vaccination | |
| AU2004270275B2 (en) | Lentivirus vector-based approaches for generating an immune response to HIV humans | |
| JP2007505130A5 (OSRAM) | ||
| Joseph et al. | A safe, effective and affordable HIV vaccine—an urgent global need | |
| WO2017088053A1 (en) | Dual-action vaccines (dav) to prevent hiv and ebola virus infections | |
| TW202423456A (zh) | 表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體 | |
| King et al. | Troubleshooting methods for the generation of novel pseudotyped viruses | |
| McKenna | Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins | |
| Fitzgerald | Induction of human immunodeficiency virus type 1 gag-specific CD8+ T cells by recombinant E1-deleted simian adenovirus vectors | |
| Diederich et al. | Virus-Like Particles | |
| Sharkey | Production and analysis of alphaviral glycoprotein-pseudotyped retroviruses | |
| Maamary | Live attenuated viral vaccine vectors |